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Enzastaurin-induced apoptosis in glioma cells is
caspase-dependent and inhibited by BCL-XL
Abstract
The novel protein kinase C-beta inhibitor enzastaurin (ENZA) induced apoptosis in LNT-229 and T98G
cells whereas A172 cells were resistant. Further, ENZA reduced proliferation in glioblastoma-initiating
cells T 269 and T 323 but did not induce apoptosis. ENZA-induced apoptosis involved cleavage of
caspases 3, 8, and 9 and led to mitochondrial cytochrome c release and was strongly suppressed by the
broad spectrum caspase inhibitor zVAD-fmk but only slightly by the expression of the viral caspase 1/8
inhibitor cytokine response modifier-A. ENZA did not reduce the phosphorylation of protein kinase B
(Akt), but of p70 S6 kinase and of its substrate S6 protein in T98G cells. Inhibition of the
phosphatidylinositol 3 kinase signaling pathway did not restore sensitivity of A172 cells towards ENZA,
and constitutively active Akt did not protect LNT-229 and T98G cells from ENZA-induced apoptosis.
Dephosphorylation of glycogen synthase kinase 3beta, a biomarker of ENZA action, and cell death
induction by ENZA were separately regulated. Inhibition or activation of Akt only weakly modulated
ENZA-induced dephosphorylation of glycogen synthase kinase 3beta. In ENZA-resistant A172 cells,
apoptosis ligand 2 (Apo2L.0)-induced cleavage of caspases 3, 8, and 9 was increased by ENZA,
resulting in synergistic activity of ENZA and Apo2L.0.
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Abstract 
The novel protein kinase C (PKC)-β inhibitor enzastaurin (ENZA) induced apoptosis 
in LNT-229 and T98G cells whereas A172 cells were resistant. Further, ENZA 
reduced proliferation in glioblastoma-initiating cells T 269 and T 323 but did not 
induce apoptosis. ENZA-induced apoptosis involved cleavage of caspases 3, 8 and 9 
and led to mitochondrial cytochrome c release and was strongly suppressed by the 
broad spectrum caspase inhibitor zVAD-fmk but only slightly by the expression of the 
viral caspase 1/8 inhibitor cytokine response modifier-A. ENZA did not reduce the 
phosphorylation of protein kinase B (Akt), but of p70 S6 kinase and of its substrate 
S6 protein in T98G cells. Inhibition of the phosphatidylinositol 3 kinase signaling 
pathway did not restore sensitivity of A172 cells towards ENZA, and constitutively 
active Akt did not protect LNT-229 and T98G cells from ENZA-induced apoptosis. 
Dephosphorylation of glycogen synthase kinase 3β (GSK-3β), a biomarker of ENZA 
action, and cell death induction by ENZA were separately regulated. Inhibition or 
activation of Akt only weakly modulated ENZA-induced dephosphorylation of GSK-
3β. In ENZA-resistant A172 cells, Apo2L.0-induced cleavage of caspases 3, 8 and 9 
was increased by ENZA, resulting in synergistic activity of ENZA and Apo2L.0.  
Key words: Apo2L, apoptosis, caspases, enzastaurin, GSK-3β, glioma-initiating 
cells. 
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Abbreviations used: 
Apo2L/TRAIL, Apo2 ligand/TNF-related apoptosis-inducing ligand; bFGF, basic 
fibroblast growth factor; CD95L, CD95 ligand; crm-A, cytokine response modifier-A; 
DMEM, Dulbecco’s Modified Eagle’s Medium; ECL, enhanced chemiluminescence; 
EGF, epidermal growth factor; ENZA, enzastaurin; EGFR, epidermal growth factor 
receptor; ERK, extracellular related kinase; FCS, fetal calf serum; GSK-3β, glycogen 
synthase kinase 3β; GFP, green fluorescent protein; HRP, horseradish peroxidase; 
LIF, leukemia inhibitory factor; MGMT, methyl-guanly-methyl transferase; mTOR, 
mammalian target of rapamycin; NSCM, neural stem cell medium; PMSF, 
phenylmethylsulfonylfluoride; PDK-1, protein 3-phosphoinositide-dependent kinase 1; 
PI, propidium iodide; PKB/Akt, protein kinase B; PKC, protein kinase C; PI3K, 
phosphatidylinositol 3 kinase; SDS-PAGE, sodium dodecyl sulphate polyacrylamide 
gel electrophoresis; SFM, serum-free medium; TNF, tumor necrosis factor; VEGF, 
vascular endothelial growth factor. 
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Introduction 
Protein kinase C (PKC) proteins are serine/threonine protein kinases that exert an 
important function in signal transduction pathways mediating cell growth and survival 
of normal and tumor cells (Gutcher et al. 2003). PKC is constitutively activated in 
malignant glioma cells (da Rocha et al. 2002). Further key properties of malignant 
gliomas include (i) reduced proliferation in response to staurosporine- or CGP41251-
induced inhibition of PKC (Baltuch & Yong 1996; Yamasaki et al. 2003) and (ii) 
increased apoptosis mediated by staurosporine (Couldwell et al. 1994) and by 
downregulation of PKC-ε (Okhrimenko et al. 2005). Altogether, these data suggest a 
survival function for PKC in glioma cells. 
ENZA (LY317615.HCl) is a novel, orally available small-molecule PKC inhibitor with 
increased selectivity for PKC-β isoforms. It elicits anti-tumoral activity and is currently 
under clinical investigation (Carducci et al. 2006). One proposed mechanism 
underlying its antitumor effects is inhibition of angiogenesis. PKC is required for 
tumor-induced angiogenesis, and inhibition of PKC by the PKC-β-selective inhibitor 
LY333531 inhibited the vascular endothelial growth factor (VEGF)-induced growth of 
hepatocellular carcinoma (Yoshiji et al. 1999). Similarly, ENZA exerted anti-
angiogenic properties in a rat corneal micropocket (Teicher et al. 2002) and in tumor 
xenografts (Keyes et al. 2004). 
Furthermore, ENZA induced apoptosis in HCT116 colon carcinoma cells and in 
multiple myeloma cells as well as U87MG glioma cells and inhibited tumor growth in 
a xenograft model (Graff et al. 2005; Rizvi et al. 2006). ENZA-induced apoptosis was 
associated with suppression of the Akt signaling pathway. Additionally, glycogen 
synthase kinase 3β (GSK-3β) was dephosphorylated during treatment with ENZA in 
vitro and in an U87MG xenograft model (Graf et al. 2005). Hence, GSK-3β 
dephosphorylation has been suggested to be a pharmacodynamic marker of ENZA 
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activity. In addition, treatment of T cell lymphoma cell lines with ENZA induced 
apoptosis associated with dephosphorylation of protein kinase B (PKB)/Akt (Querfeld 
et al. 2006). Recently, we reported synergistic effects of ENZA and irradiation in both 
the induction of apoptosis in vitro and the treatment of orthotopic LNT-229 gliomas in 
nude mice (Tabatabai et al. 2007). Here, we investigated the mechanisms underlying 
ENZA-induced glioma cell apoptosis and the role of ENZA-dependent 
dephosphorylation of Akt and GSK-3β in that process. 
 
 5
Materials and Methods 
Materials. All chemicals were purchased from Sigma (Deisenhofen, Germany) unless 
otherwise indicated. LY294002, an inhibitor of phosphatidylinositol 3 kinase (PI3K), 
was obtained from Calbiochem (Schwalbach, Germany). Wortmannin, another 
inhibitor of PI3K, the caspase inhibitor zVAD-fmk and Ac-DEVD-amc were from 
Bachem (Weil am Rhein, Germany). ENZA was provided by Eli Lilly (Indianapolis, 
IN). It was solubilized in DMSO at 10 mM and stored at -20°C.  As a control, DMSO 
was used in the experiments. Apo2L.0 was provided by A. Ashkenazi (Ashkenazi et 
al. 1999). 
Cell culture. The glioma cell lines have been described previously. Glioma cells were 
maintained in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal calf 
serum (FCS), 100 IU/ml penicillin and 100 ng/ml streptomycin (Cambrex, Verviers, 
Belgium). LNT-229 neo control transfected cells and LNT-229 BCL-XL expressing as 
well as T98G puro control transfected cells and T98G cytokine response modifier-A 
(crm-A) cells were generated as described (Wagenknecht et al. 1998; Steinbach et 
al. 2003).  
Primary tumor spheres. Tumor samples were obtained from adult patients diagnosed 
with glioblastoma after informed consent. The technique to obtain tumor and 
neurosphere cultures was modified from Svendsen et al. (1998). Briefly, tissue was 
washed, minced, digested with trypsin, dissociated, and passed through a 100 µm 
cell strainer. Cells were seeded in neural stem cell medium (NSCM) containing 
DMEM:F12 growth medium enriched with B27 supplement, basic fibroblast growth 
factor (bFGF) (20 ng/ml), epidermal growth factor (EGF) (20 ng/ml) and leukemia 
inhibitory factor (LIF) (20 ng/ml) (Hemmati et al. 2003). To obtain adherent, 
differentiated cells, tumor cells were cultured in serum-containing medium (10% FCS) 
in parallel. 
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 Crystal violet staining. For crystal violet staining, glioma cell lines were seeded at 
20,000 cells per well in 96-well plates in DMEM/10% FCS. After 24 h, medium was 
removed, cells were treated in serum-free medium (SFM) as indicated, and viable 
cells were stained with crystal violet. 
Trypan blue staining. Glioma cells were seeded at 50,000 cells per well in 24-well 
plates in DMEM/10% FCS. After 24 h, medium was removed, and cells were treated 
as described in SFM for 48 h. Thereafter, cells and supernatants were collected, 
trypan blue solution was added, and unstained and trypan blue-stained cells were 
counted. 
Self-renewal capacity. Self-renewal was measured after primary sphere formation 
was noted. Spheres were kept in NSCM, and their differentiated counterparts were 
kept in SFM with 10% FCS. In case spheres did not have a counterpart that grew in 
serum-containing medium, self-renewal of the spheres was determined in NSCM 
compared to the number of colonies growing under differentiation-inducing conditions 
with 10% FCS. After dissociation, cells were plated in 96-well microwell plates in 0.2 
ml volumes of NSCM or medium with 10% FCS at 75 cells/well. Twelve wells were 
plated per experiment. Cultures were supplemented with 0.025 ml of NSCM or 
medium with 10% FCS every 3 days until day 7. At day 7, the number of colonies per 
well was counted after fluorescence labelling of the cells with MitoTracker Red 
(Invitrogen, Karlsruhe, Germany). Sensitivity to ENZA at 5 µm was analyzed by 
plating the cells in ENZA-containing medium. 
Proliferation. Neurosphere cells at 10.000 cells/well and their differentiated 
counterparts were dissociated and plated in quadruplicates in 96-well plates in 200 µl 
volumes of NSCM and SFM supplemented with 10% FCS. To assess radio- or 
chemosensitivity, cells were treated as described above. After 24 h, cells were pulsed 
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for another 24 h with [methyl-3H]thymidine (0.5 µCi), harvested (Tomtec, Hamden, 
CT), and incorporated radioactivity was determined in a liquid scintillation counter 
(Wallac, Turku, Finland) (Uhl et al. 2004).  
Immunoblot analysis. Cells were treated as described in SFM. Thereafter, cells were 
washed with ice-cold phosphate-buffered saline (PBS) and harvested into PBS with 
phenylmethylsulfonylfluoride (PMSF). The cells were centrifuged, lysed in lysis buffer 
P (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 100 µg/ml 
PMSF) containing 10 µg/ml leupeptin, 2 µg/ml aprotinin and phosphatase inhibitor 
cocktails 1 and 2, and subjected to sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE). For detection of phosphorylated proteins, tris-buffered 
saline (TBS) was used instead of PBS. Membranes were probed overnight with the 
following antibodies: anti-phospho-extracellular related kinase (ERK)1/2 (No. 9106), 
anti-phospho-AktSer473 (No. 92715), anti-phospho-AktThr308 (No. 4056), anti-Akt (No. 
9272), anti-phospho-p70 S6 kinase (No. 9205), anti-p70 S6 kinase (No. 9202), anti-
phospho-S6 protein (No. 2211), anti-S6 protein (No. 2217), anti-phospho-mammalian 
target of rapamycin (mTOR) (No. 2971), anti-mTOR (No. 2972), anti-cleaved-
caspase 3 (No. 9661), anti-phospho-GSK-3β (No. 9336), anti-caspase-9 (No. 9508) 
from Cell Signaling (Frankfurt, Germany), anti-ERK1/2 (sc 94), anti-β−Actin (sc 
1616), anti-BCL-2 (sc 509) from Santa Cruz (Heidelberg, Germany), anti-crm-A (No. 
556427), anti-BCL-XL (No. 556499) and anti-cytochrome c (No. 556433) from 
Pharmingen (Heidelberg, Germany), anti-caspase-8 (ALX-804-429-C100) from Alexis 
(Grünberg, Germany), anti-Bid (AG 1730) from Chemicon, and anti-GSK-3β (No. 
610201) from BD Transduction Laboratories. The secondary antibodies horseradish 
peroxidase (HRP)-conjugated anti-mouse IgG, anti-goat IgG and anti-rabbit IgG were 
from Santa Cruz. Enhanced chemiluminescence (ECL) from Amersham 
(Braunschweig, Germany) was used for detection. 
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Analysis of cytochrome c release. After treatment, the cells were centrifuged, and 
incubated for 10 min in 600 µl MSH buffer (210 mM D-mannitol, 70 mM sucrose, 10 
mM HEPES, 200 µM EGTA, 5 mM succinate, 0.15% bovine serum albumine) 
containing digitonin (40 µg/ml) at 4°C. The buffer was removed and centrifuged at 
13,000 rpm. The supernatant was transferred to another cup, and 600 µl of 
trichloracetic acid 10% was added. After incubation for 30 min at -20°C and 
centrifugation at 13,000 rpm, the supernatant was removed, and the cups were dried. 
Thereafter, 50 µl Laemmli buffer, diluted in lysis buffer P, and 1 µl mercaptoethanol 
was added. After denaturating for 5 min at 95°C, 25 µl were used for cytochrome c 
immunoblot analysis. 
Cell cycle analysis. The cells were treated as described. Detached cells were 
collected, adherent cells were trypsinized and added to the detached cells, and 
washed with PBS. Thereafter, cells were incubated for 30 min with ethanol 50%, 
washed with PBS, and incubated with propidium iodide (50 µg/ml) for 20 min, and 
analyzed in a DAKO CyAn flow cytometer (Glostrup, Denmark). 
Methyl-guanly-methyl-transferase (MGMT) promoter analysis. A tumor cell content of 
at least 80% was histologically determined. From each sample and the reference 
samples 200 to 500 ng of genomic DNA were treated with sodium bisulfite using the 
Qiagen EpiTect kit (Qiagen, Hilden, Germany) with the provided FFPE tissue 
protocol. The primer sequences used to detect methylated MGMT promoter 
sequences were 5′-tttcgacgttcgtaggttttcgc-3′ and 5′-gcactcttccgaaaacgaaacg-3′. This 
primer combination amplifies an 81-base pair (bp) fragment from methylated DNA. 
The primer sequences used to detect unmethylated MGMT promoter sequences 
were 5′-aactccacactcttccaaaaacaaaaca-3′ and 5′-tttgtgttttgatgtttgtaggtttttgt-3′. This 
primer combination amplifies a 93-bp fragment from unmethylated DNA (Esteller et 
al. 2000). The PCR products were separated on 2.5% agarose gels. As a positive 
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control for methylation, we used genomic DNA from the glioma cell line U87 with 
known MGMT hypermethylation. CpGenome universal unmethylated DNA Vial A 
(Chemicon International, Temecula, CA) served as a negative control for methylation. 
In addition, a control reaction without any template DNA was performed for both PCR 
experiments. 
CD 133 magnetic cell sorting and flow cytometry. After sphere formation, cells were 
digested with accutase and mechanically dissociated. They were resuspended in 
PBS with 0.5% BSA and 2 mM EDTA. Magnetic labeling with CD133/1 microbeads 
was performed using the Miltenyi Biotec CD133 Cell Isolation kit. Ten µl of CD133/2-
phycoerythrin (fluorochrome-conjugated mouse monoclonal IgG1; Miltenyi Biotec, 
Bergisch Gladbach, Germany) were added for 30 min to evaluate the efficiency of 
magnetic separation by flow cytometry. Magnetic separation was carried out on the 
autoMACS machine (Miltenyi Biotec). Positive and negative fractions were eluted 
with a double-sensitive mode. Aliquots of CD133+ and CD133- sorted cells were 
evaluated for purity by flow cytometry with a CyAn flow cytometry analyzer (Dako). 
CD133+ and CD133- sorted cell populations were resuspended in NSCM with growth 
hormones. 
To assess the amount of CD133+ and CD133- in an unsorted cell culture, cells were 
dissociated and stained with Anti-CD133/1-PE or CD133/2-PE antibody (Miltenyi 
Biotec) as described in the users guide. As positive controls for CD133 WERI Rb-1 
cells cultured in RPMI-1640 with L-glutamine (GIBCO BRL, Grand Island, NY), 
supplemented with 10% FCS were used. Cells were regarded to be CD133 positive 
when the specific fluorescent index exceeded 1.3.   
Ac-DEVD-amc cleavage assay. For the Ac-DEVD-amc cleavage assay indicative of 
caspase 3/7 activity, 10,000 cells per well were seeded in 96-well plates in DMEM 
containing 10% FCS. After 24 h, the cells were treated as indicated in SFM. Medium 
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was removed, and 50 µl lysis buffer P diluted 1:2 with PBS per well was added. After 
10 min, 50 µl Ac-DEVD-amc dissolved in PBS at 25 µM was added and incubated for 
60 min at 37°C. Thereafter, Ac-DEVD-amc cleavage was analyzed using a Mithras 
LB940 Microplate Reader (Berthold Technologies, Bad Wildbad, Germany). Relative 
Ac-DEVD-amc cleavage is expressed relative to control treated samples. 
Transient transfections. For transient transfections, LNT-229 cells were transfected 
with a GFP control plasmid or  a H-PKBa(DD)/pEGFPC3 plasmid expressing a 
constitutive active GFP-Akt fusion protein using Metafectene pro (Biontex, 
Martinsried, Germany). If at least 50% of the cells were transfected as analyzed by 
fluorescence microscopy 12 h after transfection, the cells were used for the 
subsequent experiments. 
Statistical analysis. Statistical significance was assessed by unpaired t-test (Excel, 
Microsoft, Seattle, WA). Synergy was determined by the fractional product method. A 
difference of more than 10% between observed and predicted effect was considered 
to signify synergistic activity. 
 
 11
Results 
ENZA induces apoptosis in glioma cells. ENZA at 5 µM reduced the survival of T98G 
cells whereas ENZA inhibited proliferation in A172 cells but did not lead to cell death 
in a time-dependent manner as observed in T98G cells (Fig. 1a). In primary glioma 
cells, designated as glioblastoma-initiating cells and kept in NSCM, T 269 and T 323, 
proliferation and self-renewal capacity were reduced with clinically relevant doses of 
ENZA. Interestingly, no differential sensitivity was observed between T 323 cells 
either kept in NSCM or in differentiating conditions (Fig. 1b). To further characterize 
the type of cell death, we analyzed the cell cycle distribution of ENZA-treated cells by 
flow cytometry. In T98G cells, treatment with ENZA resulted in an increase of the 
sub-G1 fraction, indicating induction of apoptosis. Furthermore, we observed a 
reduction of the G1 peak in these cells. There were no distinct alterations in the cell 
cycle distribution in ENZA-treated A172 cells, suggesting a cell cycle-independent 
growth inhibition (Fig. 1c). With the objective of more closely modeling the clinical 
situation, we also analyzed freshly prepared glioma cells that in low quantities give 
rise to glioma in nude animals and form spheroids (data not shown) and are therefore 
designated glioma-initiating cells. Both cells were also positive for CD133, a marker 
linked to glioma-initiating cells in some studies, and showed a methylated promoter of 
the MGMT gene in T 323 and an unmethylated MGMT promoter in T 269 cells. 
However, there were no alterations in the cell cycle distribution in ENZA-treated T 
269 and T 323 cells, indicating that these cells did not undergo apoptosis in response 
to ENZA as analyzed by flow cytometry (data not shown). 
 
ENZA induces activation of caspases and release of cytochrome c. We next 
investigated the levels of proteins important for the execution of apoptosis. In T98G 
cells, ENZA induced the cleavage of caspases 3, 8 and 9 (Fig. 2a). No caspase 
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cleavage was detectable in A172 cells. Similarly, increased Ac-DEVD-amc cleavage 
was detected in ENZA-treated T98G but not in A172 cells (Fig. 2b). As the two 
mitochondrial proteins BCL-2 and BCL-XL are known to be important modulators of 
apoptosis, we also examined the levels of these proteins. Neither BCL-2 nor BCL-XL 
levels were consistently altered in response to ENZA (Fig. 2a). We also examined 
possible changes in Bid levels. Cleavage of Bid by caspase 8 has been shown to 
connect the death ligand-induced apoptotic signal to the mitochondria (Li et al. 1998). 
However, we did not detect cleavage of Bid in ENZA-treated cells (Fig. 2a). 
Additionally, ENZA induced a strong release of cytochrome c into the cytosol in T98G 
cells, but not in A172 cells (Fig. 2c, not shown). These results suggest that caspases 
are activated via mitochondrial cytochrome c release during ENZA-induced 
apoptosis.  
 
Caspases are critical for induction of cell death by ENZA. To figure out whether the 
observed activation of caspases is critical for ENZA-induced cell death, we analyzed 
cell death in T98G cells treated with ENZA in the presence of the caspase inhibitor 
zVAD-fmk. zVAD-fmk inhibited cell death as well as ENZA-induced activation of 
caspases in T98G cells (Fig. 3a). Compared with untreated cells, the reduced density 
of cells co-treated with ENZA and zVAD-fmk indicates that ENZA induced growth 
inhibition in the presence of zVAD-fmk. Furthermore, the formation of a sub-G1 peak 
induced by ENZA was largely prevented by zVAD-fmk (Fig. 3b). To investigate 
whether the activation of caspase 8 is fundamental to the induction of cell death, 
T98G cells expressing the viral caspase 1/8 inhibitor crm-A were exposed to ENZA. 
Crm-A inhibited ENZA-induced cell death only insignificantly, suggesting that 
caspase 8 does not relevantly contribute to ENZA-induced cell death. Control 
experiments demonstrated that CD95 ligand (CD95L)-induced apoptosis was 
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strongly prevented by crm-A, and zVAD-fmk also inhibited cell death induced by 
ENZA and CD95L ligand (Fig. 3c). 
 
Modulation of ENZA-induced apoptosis by BCL-XL. The cytochrome c release 
exerted by ENZA suggests an ENZA-mediated induction of the mitochondria-
dependent cell death pathway that is known to be negatively influenced by 
antiapoptotic members of the BCL-2 protein family, namely BCL-2 or BCL-XL. We 
therefore analyzed whether the ectopic expression of BCL-XL in glioma cells inhibits 
ENZA-induced apoptosis. We stably transfected human T98G or LNT-229 cells with 
a plasmid expressing the human bcl-xL gene. Transgene expression was lower in 
T98G cells than in LNT-229 cells. Therefore, we used LNT-229 cells in these 
experiments. BCL-XL strongly suppressed ENZA-dependent induction of cell death, 
release of cytochrome C (data not shown) and cleavage of Ac-DEVD-amc (Fig. 4a-c). 
Compared with control transfectants, T98G cells over-expressing BCL-XL were also 
protected against ENZA-induced cell death (data not shown). 
 
Modulation of survival signaling pathways by ENZA. We next investigated alterations 
of signaling in response to ENZA-treatment in glioma cell lines sensitive or resistant 
to ENZA. Activation of the Akt signaling pathway was examined by determination of 
Thr308 and Ser473 phosphorylation. In T98G cells, but not in A172 cells, 
phosphorylation of AktSer473 was diminished by serum withdrawal. In contrast, 
AktThr308 phosphorylation was increased at 24 h after treatment with ENZA in both 
T98G and A172 cells. In T98G cells, phosphorylation of AktSer473 was also increased 
by ENZA at 1 h and 2 h whereas in A172 cells, phosphorylation remained 
unchanged. Phosphorylation of ERK1/2 was induced in both cell lines in response to 
ENZA for 3 h to 24 h. As expected from the mechanism of action (Graff et al. 2005) 
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and in line with our data observed with LNT-229 cells (Tabatabai et al. 2007), ENZA 
resulted in a strong dephosphorylation of GSK-3β in both cell lines. Moreover, 
phosphorylation of mammalian target of rapamycin (mTOR) was reduced in T98G 
cells in response to treatment with ENZA at 6 h and 24 h. We next analyzed 
activation of p70 S6 kinase that is phosphorylated by protein 3-phosphoinositide-
dependent kinase 1 (PDK-1) and Akt (Shamji et al. 2003), and of its substrate S6 
protein. In ENZA-sensitive T98G cells, phosphorylation of p70 S6 kinase and S6 
protein was reduced after 6 h and 24 h. In contrast, phosphorylation of p70 S6 kinase 
and S6 protein in A172 cells remained unaltered within 24 h (Fig. 5A) and even after 
prolonged ENZA-treatment for 48 h (Fig. 5b). We also examined phosphorylation of 
p70 S6 kinase and S6 protein in LNT-229 neo and LNT-229 BCL-XL cells and found 
that phosphorylation of both kinases was similarly reduced in both transfectands in 
response to treatment with ENZA. Furthermore, we also detected reduced 
phosphorylation of GSK-3β in LNT-229 neo and BCL-XL cells in response to ENZA 
(Fig. 5c). 
 
Role of Akt in ENZA-dependent induction of cell death. As dephosphorylation of Akt 
has been suggested to be crucial for ENZA-induced cell death (Graff et al. 2005), we 
aimed at investigating the role of PI3K signaling in ENZA-induced cell death. First, we 
examined whether inhibition of PI3K sensitized A172 cells towards ENZA. Efficient 
inhibition was obtained at 2 h of treatment with the PI3K inhibitor LY294002, as 
demonstrated by the loss of AktSer473  dephosphorylation (Fig. 6a, upper panel). In 
contrast, treatment with ENZA alone had no influence on Akt phosphorylation, 
consistent with the results shown in Fig. 2a. However, combined treatment with 
ENZA and LY294002 resulted in a sustained dephosphorylation of AktSer473 at 24 h, 
whereas treatment with ENZA or LY294002 alone had not such an effect during that 
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time interval (Fig. 6a, upper panel). We next determined phosphorylation of GSK-3β 
in A172 cells in response to treatment with ENZA or LY294002: ENZA but not 
LY294002 inhibited the phosphorylation of GSK-3β. Further, we did not observe 
activation of caspase 3 cells by ENZA in A172, LY294002, or both at 2 or 24 h. In line 
with these results, LY294002 reduced growth of A172 cells but did not sensitize them 
towards ENZA-induced cell death (Fig. 6a, lower panel). These experiments indicate 
that Akt signaling is not underlying the mechanism of resistance towards ENZA in 
A172 cells. Additionally, we asked whether the inhibition of Akt is a relevant 
mechanism of ENZA in sensitive cells. Therefore, LNT-229 and T98G cells that are 
both sensitive to ENZA-induced apoptosis were transiently transfected with a plasmid 
encoding constitutively active Akt fused to GFP or with the respective GFP control 
plasmid. Since transfection rates were again higher in LNT-229 cells, data derived 
from experiments performed with this cell line are presented: Serum withdrawal 
strongly reduced the Akt-mediated phosphorylation of p70 S6 kinase in control 
transfected cells (Fig. 6b). In Akt transfected LNT-229 cells, phosphorylation of p70 
S6 kinase was partially maintained despite serum withdrawal, indicating the 
functionality of ectopically expressed Akt. Dephosphorylation of GSK-3β through 
ENZA was slightly inhibited by Akt. Unlike T98G or A172 cells, in LNT-229 cells, Akt 
phosphorylation was reduced in response to treatment with ENZA for 24 h. However, 
ectopic expression of Akt in LNT-229 cells did not inhibit ENZA-induced apoptosis 
(Fig. 6b). Similarly, we did not observe protection from ENZA-induced cell death by 
expression of Akt in T98G cells (data not shown). 
 
ENZA increases Apo2L.0-induced cell death. We have recently shown that ENZA 
and radiotherapy act synergistically in inducing cell death (Tabatabai et al. 2007). 
Moreover, caspase 8, an initiator caspase of death receptor-mediated apoptosis, was 
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cleaved in response to ENZA-treatment in T98G cells (Fig. 2a). Therefore, we 
speculated whether ENZA modulates cell death induced by the tumor necrosis factor 
(TNF) family member Apo2 ligand/TNF-related apoptosis-inducing ligand 
(Apo2L/TRAIL). Treatment with Apo2L.0 at 10 ng/ml for 20 h did not induce cell death 
in T98G or A172 cells whereas combined treatment with Apo2L.0 and ENZA at 5 µM 
synergistically reduced survival in T98G and in A172 cells, as well as in the 
glioblastoma-initiating cells, T 269 and T 323 (data not shown). Therefore, we 
examined the underlying mechanisms in T98G and A172 cells when co-exposed to 
Apo2L.0 and ENZA. As shown in Fig. 7, Apo2L.0 induced activation of caspase 3 in 
T98G cells, which was further increased by combined treatment with Apo2L.0 and 
ENZA. In contrast, caspase 8 was not cleaved in response to treatment with Apo2L.0 
alone in T98G cells, whereas combined treatment of Apo2L.0 and ENZA induced 
cleavage of caspase 8. A similar result was found for caspase 9. In A172 cells, ENZA 
increased Apo2L.0-induced cleavage of caspases 3, 8 and 9. 
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Discussion 
ENZA is a novel PKC-β inhibitor with antitumor activity that is currently under clinical 
investigation in several tumor entities including recurrent and newly diagnosed 
glioblastoma (Carducci et al. 2006). Several mechanisms by which ENZA exerts its 
antitumor effects have been described: First, ENZA has been shown to have 
antiangiogenic properties associated with decreased VEGF levels (Keyes et al. 
2004). Supporting these observations, antiglioma activity of ENZA has been shown in 
a mouse xenograft model (Tabatabai et al. 2007). In these experiments, it was further 
observed that treatment with ENZA resulted in synergistic activity with irradiation and 
reduced expression of VEGF in vitro and in vivo leading to reduced vessel density in 
glioma xenografts. Second, ENZA has direct cell death-inducing properties in tumor 
cells in vitro (Graff et al. 2005). Still, the mechanisms of ENZA-dependent cell death 
induction have remained unclear. Recently, for gastric cancer cells, it has been 
shown that ENZA induces apoptosis through ribosomal S6 kinase (Rsk)- and Bad-
mediated pathways, besides inhibiting the Akt signaling cascade (Lee et al. 2008). 
In the work at hand, we observed that ENZA at clinically achieved concentrations 
(Rademaker-Lakhai et al. 2007; Robertson et al. 2007; Carducci et al. 2006) induced 
apoptosis in LNT-229 (Tabatabai et al. 2007) and T98G glioma cells, but not in A172 
glioma cells (Fig. 1, 6), indicating that ENZA-induced cell death is not a general but 
rather a cell type-specific phenomenon. Therefore, we comparatively used T98G 
(sensitive) and A172 (resistant) glioma cells in our experiments. However, primary 
glioma cells, designated as glioma-initiating cells show reduced proliferation and self-
renewal but no cell death in response to ENZA. This underlines the relevance of 
ENZA treatment and suggests an effect of ENZA not only on the tumor bulk but also 
on cells that are thought to maintain tumor growth (Gilbertson & Rich 2007). 
However, specific resistance mechanisms might be in place in the resistance to cell 
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death in the glioma-initiating cell subgroup (Fig. 1b). In a gene expression analysis of 
cases from the EORTC 26981/NCIC CE 3.0 study CD133, expression of epidermal 
growth factor receptor (EGFR) and MGMT promoter methylation status were 
independent prognostic factors, with MGMT conferring an additional predictive value 
for the response to chemotherapy (Murat et al. 2008). However, in our analysis, 
MGMT promoter methylation done for both tumors (T 269 unmethylated and hence 
active and T323 methylated and hence inactive) in the clinical setting, as expected, 
does not explain the resistance to ENZA, which does not have alkylating properties. 
In addition, CD133 expression in our hands does not discriminate between ENZA-
sensitive and -insensitive tumors (data not shown). A larger study of the EORTC on 
the EGFR inhibition demonstrated no predictive value of EGFR expression but also a 
merely prognostic value (van den Bent et al. 2007). Analysis of the signaling 
pathways underlying ENZA-induced cell death could help to understand the 
differential sensitivity and might lead to efficient combination treatments with ENZA.  
ENZA-treatment of T98G and LNT-229 cells, but not of A172 cells, resulted in the 
activation of caspases 3 and 9. Furthermore, cleavage of caspase 8, an initiator 
caspase of death receptor-mediated apoptosis, was observed in T98G cells in 
response to ENZA (Fig. 2a). However, expression of crm-A, a viral inhibitor of 
caspases 1 and 8, only weakly inhibited apoptosis, suggesting that activation of 
caspase 8 is not critical for ENZA-induced apoptosis (Fig. 3c). In contrast, the pan-
caspase inhibitor zVAD-fmk strongly inhibited ENZA-induced activation of caspases 
and apoptosis (Fig. 3). These results are in line with a report demonstrating that in 
cutanous T cell lymphoma cells ENZA-induced cell death can be inhibited by zVAD-
fmk (Querfeld et al. 2006). ENZA-dependent cleavage of caspases 3 and 8 has also 
been reported in multiple myeloma cells (Podar et al. 2007). In contrast, in the 
multiple myeloma cell line MM1.S, cell death induced by ENZA at similar 
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concentrations as in our experiments was not prevented by inhibition of caspases 
(Rizvi et al. 2006). Further, ENZA-induced apoptosis was associated with 
mitochondrial cytochrome c release in T98G cells (Fig. 2c). In addition, expression of 
BCL-XL strongly prevented ENZA-induced cell death. These results suggest that 
ENZA induces cell death in glioma cells via the „intrinsic“ cell death pathway (Igney & 
Krammer 2002) that is associated with the release of mitochondrial cytochrome c and 
can be inhibited by antiapoptotic members of the BCL-2 protein family. 
It has been proposed that ENZA-induced cell death is a result of inhibition of the 
PI3K signaling pathway because treatment with ENZA was associated with reduced 
phosphorylation of Akt in several tumor cell lines (Moreau et al. 2007; Querfeld et al. 
2006; Graff et al. 2005). However, ENZA, though inducing cell death, did not reduce 
Akt phosphorylation in T98G glioma cells (Fig. 5) although others have observed this 
in the same cells, possibly reflecting a very late event in the dying cells (Jane and 
Pollack 2008). Furthermore, inhibition of the PI3K signaling pathway did not restore 
sensitivity of A172 cells towards ENZA. Importantly, expression of constitutive Akt 
protected neither LNT-229 nor T98G cells from ENZA-induced apoptosis (Fig. 6b and 
data not shown). Together, these results suggest that in the glioma cell lines 
examined in our experiments, ENZA-induced apoptosis does not involve inhibition of 
the PI3K signaling pathway. In T98G cells, we observed reduced phosphorylation of 
p70 S6 kinase and of its substrate S6 protein in response to treatment with ENZA, 
wheras in A172 cells, phosphorylation of p70 S6 kinase and of S6 protein remained 
unaltered. With regard to the literature, ENZA has also been reported to result in 
reduced phosphorylation of S6 protein in colon carcinoma cells (Graff et al. 2005), in 
cutaneous lymphoma cells (Querfeld et al. 2006), in Waldenstrom macroglobulinemia 
cells (Moreau et al. 2007) and in gastric cancer cells (Lee et al. 2008). Similarly to 
ENZA-sensitive control-transfected LNT-229 neo cells, we found that ENZA-resistant 
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BCL-XL-overexpressing LNT-229 cells also responded to ENZA treatment with 
decreased phosphorylation of p70 S6 kinase and of S6 protein. Therefore, 
dephosphorylation of p70 S6 kinase is probably not an epiphenomenon occuring 
during cell death. It might be a consequence of signaling alterations associated with 
cell death induced by ENZA upstream of the mitochondria where inhibition of cell 
death by BCL-XL probably occurs. Supporting these speculations, we observed 
reduced phosphorylation of p70 S6 kinase in response to treatment with ENZA for 6 
h (Fig. 5), whereas we detected activation of caspases only after longer treatment 
periods (Fig. 2a). Since ENZA inhibited phosphorylation of p70 S6 kinase in T98G 
cells without inhibiting phosphorylation of Akt (Fig. 1), it seems that the ENZA-
mediated decrease of phosphorylation of p70 S6 kinase is not a result of PI3K 
signaling inhibition. Therefore, the mechanisms by which ENZA inhibits 
phosphorylation of p70 S6 kinase remain elusive.  
In line with previous observations that reduced phosphorylation of GSK-3β serves as 
a surrogate marker for ENZA activity (Graff et al. 2005), we also detected 
dephosphorylation of GSK-3β in response to ENZA in glioma cells (Fig. 5). ENZA 
resulted in reduced phosphorylation of GSK-3β in ENZA-resistant A172 cells under 
the indicated conditions. In addition, expression of BCL-XL strongly inhibited ENZA-
induced cell death, but did not rescue the phosporylation of GSK-3β (Fig. 5b). 
Therefore, dephosporylation of GSK-3β and induction of cell death through ENZA are 
apparently separately regulated. It has been shown that GSK-3β can be 
phosphorylated by PKC (Goode et al. 1992) and Akt (Cross et al. 1995). Yet, 
treatment with inhibitors of the PI3K signaling pathway did not reduce 
phosphorylation of GSK-3β in A172 glioma cells (Fig. 6a), and expression of active 
Akt only marginally rescued ENZA-induced dephosphorylation of GSK-3β (Fig. 6b). 
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Therefore, phosphorylation of GSK-3β seems to be mainly controlled by PKC in the 
examined cell lines whereas the influence of Akt signaling does not seem to be 
relevant. 
How could the resistance of A172 cells towards ENZA be overcome? In A172 cells 
and in the glioblastoma-initiating cells, T 269 and T 323, Apo2L.0 induced cleavage 
of caspases 3, 8 and 9 which was enhanced by addition of ENZA, resulting in 
synergistic activity of ENZA and Apo2L.0 (Fig. 7 and data not shown). In addition to 
the synergistic effects of ENZA and radiotherapy, this is a further combined regimen 
successfully evaluating sensitization towards or by ENZA, an also provides one 
potential mechanism to overcome resistance towards APO2.L in primary glioma cells 
(Rieger et al. 2007). These data dissect the signaling cascade underlying the 
induction of apoptosis by the novel PKC-β-inhibitor ENZA and suggest activation of 
the “extrinsic” apoptosis pathway by Apo2L.0 as a measure to overcome resistance. 
In conclusion, these results demonstrate that, in some glioma cells, ENZA induces 
caspase-dependent apoptosis that is likely to be independent from PI3K signaling. 
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Figure Legends 
 
Fig. 1  ENZA induces growth arrest and DNA loss in glioma cell lines. (a) T98G or 
A172 glioma cells were vehicle-treated or treated with ENZA (5 µM) for the indicated 
times. Cell density was determined by crystal violet staining and is expressed as 
optical density (OD) (mean and SD, *, p<0.05, t-test, compared with control). (b) 
Proliferation (left axis) or self-renewal (right axis) of T 269 or T 323 cells assessed 
with a 3H-thymidine pulse for 24 h (proliferation) or by counting newly-formed 
colonies following 7 days of treatment with ENZA (5 µM) (n = 3, +, p<0.05 compared 
to controls set to 100%). (c) T98G and A172 cells were vehicle-treated or treated with 
ENZA (5 µM) for 24 h, and DNA content was assessed by flow cytometry. 
 
Fig. 2  ENZA induces activation of caspases in T98G cells. (a) T98G or A172 glioma 
cells were treated with ENZA (5 µM) as indicated, and caspase cleavage and 
expression levels of BCL-XL, BCL-2 or Bid were analyzed by immunoblot. For 
caspase 3, an antibody that detects only cleaved caspase 3 of 17 kDa and 19 kDa 
was used. The caspase 8 antibody detects uncleaved and cleaved caspase 8 as 
well. Different exposure times were used for the detection of the larger and smaller 
cleavage fragments. Similarly, the caspase 9 antibody detects uncleaved and 
cleaved caspase 9. (b) T98G and A172 cells were treated with ENZA (5 µM), and Ac-
DEVD-amc cleavage was monitored. (c) T98G cells were treated with ENZA (5 µM), 
and the release of cytochrome c was analyzed by immunoblot. 
 
Fig. 3  Activation of caspases contributes to ENZA-induced cell death. (a) Left panel: 
T98G glioma cells were vehicle-treated or treated with ENZA (5 µM), with or without 
zVAD-fmk (50 µM), for 48 h, and cell density was analyzed by crystal violet staining. 
Middle panel: T98G cells were treated as indicated for 24 h, and caspase activity was 
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analyzed by Ac-DEVD-amc cleavage assay. Right panel: T98G cells were vehicle-
treated or treated with ENZA (5 µM), with or without zVAD-fmk (50 µM), for 48 h, and 
cell death was analyzed by trypan blue staining. (b) T98G cells were treated as 
indicated for 48 h, and apoptosis was analyzed by cell cycle analysis. (c) T98G puro 
or T98G crm-A-over-expressing cells were treated as indicated with ENZA (5 µM) or 
CD95L (100 U/ml) for 48 h, and cell density was analyzed by crystal violet staining (*, 
p < 0.05, t-test, cell density of T98G puro vs. T98G crm-A cells). 
 
Fig. 4  BCL-XL inhibits ENZA-induced cell death. (a) LNT-229 neo or BCL-XL cells 
were vehicle-treated or treated with ENZA (5 µM) for 48 h, and morphology was 
analyzed by phase contrast microscopy. (b) LNT-229 neo or BCL-XL cells were 
treated for 48 h with ENZA as indicated, and cell density was analyzed by crystal 
violet staining. (c) LNT-229 neo or BCL-XL cells were treated for 24 h with ENZA as 
indicated, and caspase activity was analyzed by Ac-DEVD-amc cleavage. 
 
Fig. 5  ENZA-dependent alterations in cellular signaling pathways. (a) T98G or A172 
glioma cells were vehicle-treated or treated with ENZA (5 µM) for the indicated time 
periods. Expression of phosphorylated (P-) and total proteins as detailed was 
analyzed by immunoblot. The p70 S6 kinase antibodies detect the p70 (arrows) and 
the p85 isoforms. (b) A172 cells were vehicle-treated or treated with ENZA (5 µM) for 
1 or 48 h, and expression levels of phosphorylated and total p70 S6K, and S6 protein 
were analyzed by immunoblot. (c) LNT-229 neo and LNT-229 BCL-XL cells were 
vehicle-treated or treated with ENZA (5 µM) for 48 h, and expression levels of 
phosphorylated and total proteins GSK-3β, p70 S6 kinase and S6 protein, and of 
BCL-XL were analyzed by immunoblot. 
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Fig. 6  No function of Akt in ENZA-induced cell death. (a) Upper panel: A172 glioma 
cells were vehicle-treated or treated with LY294002 (20 µM) or ENZA (5 µM) for 2 h 
or 24 h, and expression of phospho-Akt, Akt, phospho-GSK-3β, GSK-3β, active 
caspase 3 and β-actin was analyzed by immunoblot. As a positive control for cleaved 
caspase 3, a lysate derived from LNT-229 cells treated with CD95L (100 U/ml) + 
cycloheximide (10 µg/ml) for 6 h was used (cleaved fragments indicated by arrows on 
the right side). Lower panel: A172 cells were treated as indicated for 48 h, and cell 
density was assessed by crystal violet staining. (b) Left panel: LNT-229 cells were 
transiently transfected with GFP (Control) or GFP-fused Akt (Akt), and vehicle-treated 
or treated with ENZA (5 µM) in SFM for 2 or 24 h. As a control, medium containing 
10% FCS (FCS) was used. Thereafter, expression of the indicated proteins was 
analyzed by immunoblot. The GFP-Akt fusion protein is indicated by an arrow on the 
left side. The p70 S6 kinase antibodies detect the p70 (arrows on the right side) and 
the p85 isoforms. Right panel: LNT-229 cells were transiently transfected with GFP 
(Control) or GFP-Akt (Akt). Thereafter, cells were vehicle-treated or treated with 
ENZA (5 µM) for 48 h, and cell death was analyzed by cell cycle analysis. 
 
Fig. 7  ENZA increases Apo2L.0-induced cell death. (a) T98G (left panel) and A172 
glioma cells (right panel) were treated with ENZA (5 µM), Apo2L.0 (10 ng/ml) or both 
for 20 h, and cell density was assessed by crystal violet staining. (b) T98G or A172 
cells were treated with ENZA (5 µM), Apo2L.0 (10 ng/ml) or both for 6 h, and 
cleavage of caspases 3, 8 and 9 was analyzed by immunoblot. For caspase 8, 
different exposure times were used to detect larger (upper) and smaller (lower panel) 
fragments. 
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